Kornimate/medical-research-clean huggingface dataset:
patients who die within emergency department

Conditions: Emergencies; Death

Summary: emergency services are a crowded and chaotic environment.

emergency services are a crowded and chaotic environment. aim of this study is to investigate the clinic features of emergency patients who die after brought to emergency service. this retrospective study will be conducted on patients who die within emergency department a tertiary hospital over between 01 january 2013 and 31 december 2015.

Eligibility criteria:
inclusion criteria: * patients who die within emergency department exclusion criteria: * patients who die outside emergency department patients who die before they were admitted to emergency department
pve/pvl combined with deb-tace in the treatment of patients with large and unresectable liver cancer

Conditions: Hepatocellular Carcinoma

Summary: this is a multicenter, randomized, positive parallel controlled clinical study to evaluate the short-term and long-term efficacy and safety of pvl/pve combined with deb-tace in the treatment of unresectable patients with large or large tumors in the right lobe of the liver.

most guidelines recommend transarterial chemoembolization (tace) as the standard of treatment for hepatocellular carcinoma（hcc）which is limited to the right half of the liver, single large or multiple, with / without tumor thrombus of the right branch of the portal vein.while a number of studies demonstrate poor effect of tace for patients with large hepatocellular carcinoma. portal vein embolization(pve)/portal vein ligation(pvl) is the main means to increase the future liver remnant (flr), which can reduce the complications after hepatectomy. tace on the basis of pve/pvl can not only increase flr, but also can effectively control the progression of tumor by sequential tace. this study intends to conduct a multicenter, randomized, positive parallel-controlled clinical study to objectively and scientifically evaluate the short-term and long-term efficacy and safety of ligation of the right portal vein combined with drug-eluting bead transarterial chemoembolization(deb-tace) technique in the treatment of patients with large or large tumors of the right lobe who cannot be resected in i-stage.

Eligibility criteria:
inclusion criteria: * clinically diagnosed as large or giant hepatocellular carcinoma of the right lobe of the liver; * child-pugh liver function grade a, * ecog ps 0-1 * if the tumor is resected with r0, the remaining liver volume is insufficient * icg-15r \< 30% * no serious organic diseases of heart, lung, brain and other organs; * no history of other malignant tumors; * the patient's survival time is expected to be more than 3 months. exclusion criteria: * pregnant and lactating women * history of organ transplant * tumor thrombus with portal vein trunk or left branch involved; * distant metastasis; * patients with obvious liver cirrhosis (plt \< 100 × 10 \^ 9 / l at admission or gastroscopy suggested esophageal and gastric varices); * active bleeding caused by various causes; * suffering from severe acute or chronic diseases or infectious diseases; * history of hepatectomy or tace treatment.

Keywords: drug-eluting bead transarterial chemoembolization(deb-tace) portal vein embolization(pve) portal vein ligation(pvl)
lenvatinib plus pd-1 antibody for intermediate-stage hcc beyond up-to-seven criteria

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with pd-1 antibody for patients with intermediate-stage hepatocellular carcinoma (hcc) beyond up-to-seven criteria

lenvatinib was non-inferior to sorafenib in overall survival in untreated advanced hepatocellular carcinoma, and pd-1 antibody was effective and tolerable in patients with advanced hepatocellular carcinoma. no study has evaluated the efficacy and safety of lenvatinib plus pd-1 antibody. thus, the investigators carried out this prospective study to find out it.

Eligibility criteria:
inclusion criteria: * the diagnosis of hcc was based on the diagnostic criteria for hcc used by the european association for the study of the liver (easl) * patients must have at least one tumor lesion that can be accurately measured according to easl criteria. * barcelona clinic liver cancer-stage b * beyond up-to-seven criteria (hepatocellular carcinomas with seven as the sum of the size of the largest tumor \[in cm\] and the number of tumors) * eastern cooperative oncology group performance status of 0 to 1 * no cirrhosis or cirrhotic status of child-pugh class a only * not applicable for transarterial chemoembolization, surgical resection, and local ablative therapy. * the following laboratory parameters: platelet count ≥ 75,000/μl hemoglobin ≥ 8.5 g/dl total bilirubin ≤ 30mmol/l serum albumin ≥ 30 g/l asl and ast ≤ 5 x upper limit of normal serum creatinine ≤ 1.5 x upper limit of normal inr ≤ 1.5 or pt/aptt within normal limits absolute neutrophil count (anc) \>1,500/mm3 ability to understand the protocol and to agree to and sign a written informed consent document exclusion criteria: * evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy * known history of hiv * history of organ allograft * known or suspected allergy to the investigational agents or any agent given in association with this trial. * cardiac ventricular arrhythmias requiring anti-arrhythmic therapy * evidence of bleeding diathesis. * patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry. * known central nervous system tumors including metastatic brain disease

Keywords: hepatocellular carcinoma lenvatinib pd-1 antibody bclc b stage beyond up-to-seven criteria
clinical study on the harvesting lymph nodes with carbon nanoparticles for advanced gastric cancer

Conditions: Advanced Gastric Cancer

Summary: carbon nanoparticles (cnp),with a mean size of 150 nm,can be taken up selectively by lymphatics after injection into the tissue and draining regional lymph nodes are thereby colored black,which may provide surgeons the guidance to lymph node dissection and help them harvest lymph nodes after surgery,especially some small ones. but there was insufficient evidence to justify its efficacy for those purposes.therefore,the investigators carried out a prospective randomized controlled trial on lymph node vital staining for lymph node dissection and harvesting in advanced gastric cancer to test this idea.

carbon nanoparticles (cnp),with a mean size of 150 nm,can be taken up selectively by lymphatics after injection into the tissue and draining regional lymph nodes are thereby colored black,which may provide surgeons the guidance to lymph node dissection and help them harvest lymph nodes after surgery,especially some small ones. but there was insufficient evidence to justify its efficacy for those purposes.therefore,the investigators carried out a prospective randomized controlled trial on lymph node vital staining for lymph node dissection and harvesting in advanced gastric cancer to test this idea.

Eligibility criteria:
inclusion criteria: * histologically and ct confirmed resectable advanced gastric cancer * no prior treatment * no metastases exclusion criteria: * having allergic reaction * pregnant * r0 resection is not achieved by gastrectomy with d2 lymphadenectomy according to japanese gastric cancer treatment guidelines 2010 (ver. 3)

Keywords: advanced gastric cancer carbon nanoparticles lymph nodes
nurse-led heart failure care transition intervention for african americans: the navigator program

Conditions: Heart Failure

Summary: heart failure (hf) affects over 5 million americans with hf morbidity reaching epidemic proportions. annual rates of new and recurrent hf events including hospitalization and mortality are higher among african americans. in this study, the investigators are testing an interdisciplinary model for heart failure care, with focus on enhancing self management and use of telehealth, which has significant potential to improve self management and outcomes. the main purpose of this study is to learn how to help african americans with heart failure care for themselves at home. we hope to find out if a team including a nurse and community health navigator using a computer telehealth device can help people with heart failure stay healthier. the team will help people with heart failure to manage their medication, monitor their symptoms and weigh themselves every day after they leave the hospital. the team will also help people with heart failure learn to solve problems that may keep them from following their treatment plan.


Eligibility criteria:
inclusion criteria: * hospitalized with admitting diagnosis of heart failure in prior 8 weeks * self-identified as african american * community-dwelling (i.e., not in a long-term care facility) * residence within a predefined radius in baltimore city * working telephone in their home * provide signed informed consent exclusion criteria: * cannot speak or understand english * severe renal insufficiency requiring dialysis * acute myocardial infarction within preceding 30 days * receiving home care services for hf post discharge * legally blind or have major hearing loss * screen positive for cognitive impairment on the mini-cog at baseline * unable to stand independently on a weight scale (limited ability to participate in hat system) * weigh more than 325 pounds (exceed scale capacity) * serious or terminal condition such as psychosis or cancer (actively receiving chemo or radiation) * pregnant

Keywords: heart failure self care decision support telemonitoring navigator
takepron intravenous 30 mg specified drug-use survey [acute stress ulcer and acute gastric mucosal lesions]

Conditions: Acute Stress Ulcer and Acute Gastric Mucosal Lesions

Summary: the purpose of this survey is to evaluate the safety (that is, frequency of adverse events) and efficacy (that is, hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30 milligram (mg) (takepron intravenous 30 mg ) to a large number of participants with acute stress ulcer or acute gastric mucosal lesion in daily medical practice.

this survey was designed to evaluate the safety (that is, frequency of adverse events) and efficacy (i.e., hemostatic effect, rate of rebleeding after confirmation of hemostasis) of administration of lansoprazole intravenous 30 mg (takepron intravenous 30 mg) to a large number of participants with acute stress ulcer or acute gastric mucosal lesion in daily medical practice. for adults, 30 mg of lansoprazole is typically mixed in physiological saline (jp) or 5 percent (%) glucose solution for injection (jp) and administered twice daily by drip infusion or dissolved in 20 ml of physiological saline (jp) or 5% glucose solution for injection (jp) and administered twice daily by direct slow intravenous injection.

Eligibility criteria:
inclusion criteria: * inclusion criteria: participants with the following diseases for whom oral administration is not feasible: acute stress ulcer, and acute gastric mucosal lesions (both of which should be accompanied by bleeding). exclusion criteria: -

Keywords: pharmacological therapy
perampanel titration and cognitive effects

Conditions: Epilepsy

Summary: the objective of this study is to determine whether there are any differences in the cognitive abilities and/or behavioral response of normal healthy volunteers across different titration rates of perampanel.

this is a randomized, double-blind, parallel group design across different titration rates of perampanel in healthy volunteers. the study consists of 8 visits, 4 of which will occur at the participant's home, over a 7-week period. one hundred and three (103) normal healthy subjects will be treated with perampanel (per) at one of four different titration rates: (1) 2mg/day per for one week followed by 4mg/day per for five weeks, (2) 2mg/day per for two weeks followed by 4mg/day per for four weeks, (3) 4mg/day per for six weeks, or (4) placebo (0mg/day per) for six weeks. cognitive and behavioral function testing along with safety testing will be conducted at screening, pretreatment baseline, the end of each week during the titration and maintenance period.

Eligibility criteria:
inclusion criteria: 1. healthy adults between the ages of 18 and 55 years 2. male or female (using approved birth control methods) 3. informed consent obtained exclusion criteria: 1. presence of clinically significant cardiovascular, endocrine, hematopoietic, hepatic, neurologic, psychiatric, or renal disease. 2. presence or history of drug or alcohol abuse or positive urine drug test at screening. 3. the use of concomitant medications, which are known to affect perampanel or the use of any concomitant medications that may alter cognitive function (see section viii.f for a partial list). 4. prior adverse reaction to or prior hypersensitivity to perampanel. 5. prior participation in studies involving perampanel. 6. subjects who have received any investigational drug within the previous thirty days. 7. subjects with iq \< 80 as determined by the peabody picture vocabulary test after enrollment. 8. positive pregnancy test. women of childbearing potential will be required to use approved birth control methods during the study. 9. presence of lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('yes') to either question 4 or question 5 of the c-ssrs at screening. 10. invalid results on computerized cognitive tests at screening as indicated by a 'no' on any of the validity indicators generated in the cns vital signs report.

Keywords: perampanel cognition
high-dose intensity modulated radiotherapy and concurrent chemotherapy in esophageal cancer

Conditions: Esophageal Cancer

Summary: to assess the efficacy and feasibility of high-dose intensity-modulated radiotherapy with concurrent weekly paclitaxel and cisplatin for patients with locoregionally advanced esophageal cancer

the radiation therapy oncology group (rtog) 8501 has established concurrent radiochemotherapy as the standard of care for cancer of the esophagus.however, locoregional failure remains problematic, with 25% of patients having persistence and 20% relapse of locoregional disease following the standard dose (50-50.4 gy) chemoradiotherapy . our previous phase i radiation dose escalation trial established the maximum tolerated dose of 86 gy with concurrent weekly paclitaxel and cisplatin in advanced esophageal cancer.the aim of this phase ii study is to examine the efficacy of this regimen.

Eligibility criteria:
inclusion criteria: * histologically confirmed primary squamous cell carcinoma of the esophagus * age 1 8-75. * patients must be deemed unresectable disease or patient is not deemed operable due to medical reasons. * eastern cooperative oncology group （ecog） performance status 0 to 2 * no prior radiation to the thorax that would overlap with the current treatment field. * patients with nodal involvement are eligible * adequate bone marrow, renal and hepatic functions as assessed by the following: hemoglobin \>/= 10.0 g/dl, platelet count \>/= 1 00,000/ mm\^3,absolute granulocyte count (agc) ≥2 × 10\^9 cells/l,bilirubin and aspartate transaminase ≤1.5 ×upper limit of normal (uln), creatinine \</ =1 .5 times uln. * a signed informed consent must be obtained prior to therapy. * induction chemotherapy is allowed exclusion criteria: * the presence of a fistula. * prior radiotherapy that would overlap the radiation fields. * gastroesophageal junction cancer or the lower third esophageal cancer invading the gastric wall. * uncontrolled concurrent illness including, but not limited to: chronic obstructive pulmonary disease(copd) exacerbation or other respiratory illness, serious uncontrolled infection, symptomatic congestive heart failure (chf),unstable angina pectoris, uncontrolled hypertension,or psychiatric illness/social situations that would limit compliance with the study requirements. * known hypersensitivity to paclitaxel. * any other condition or circumstance that would, in the opinion of the investigator, make the patient unsuitable for participation in the study. * acquired immune deficiency syndrome. * conditions precluding medical follow-up and protocol compliance
full thickness macular hole and internal limiting membrane peeling study

Conditions: Stage 2 or 3 Full Thickness Macular Hole

Summary: a macular hole is a fairly common problem in the retina and is an important cause of loss of central vision. the aim of this study is to determine whether, in patients with a stage 2 or 3 full thickness macular hole (ftmh), peeling a very fine, transparent tissue that covers the surface of the retina, called the internal limiting membrane (ilm) during surgery is superior to non-ilm peeling macular hole surgery. the main outcomes are improvement in vision, achievement of macular hole closure, need for re-operation, health related quality of life (hrqol) and cost effectiveness.

idiopathic full-thickness macular hole (ftmh) is an important cause of loss of central vision, usually leading to severe visual impairment. up to 20% of affected people will develop a ftmh in both eyes. there is uncertainty in the literature and among vitreo-retinal surgeons about the balance of potential benefits and adverse effects of ilm peeling in ftmh surgery for stage 2-3 holes. films is a randomised controlled trial (rct) in patients with stage 2-3 ftmh less less than 18 months duration investigating whether ilm peeling improves the anatomical and visual outcome of macular hole surgery and the quality of life of patients with this retinal disease. cost-effectiveness is also being addressed.

Eligibility criteria:
inclusion criteria: idiopathic ftmh of stage 2-3, duration of hole ≤18 months, visual acuity equal to or worse than 20/40 in the study eye. exclusion criteria: stage 1 or 4 ftmh, stage 2-3 ftmh of \> 18 months duration, visual acuity \>20/40 in study eye, ftmh related to high myopia (\>6 dioptres), ftmh related to trauma, any other causes of decreased vision (ie corneal scarring, age-related macular degeneration, diabetic retinopathy, glaucoma if central and/or paracentral absolute visual field defects present), patient unable to understand english, patient unable to give informed consent.

Keywords: full thickness macular hole internal limiting membrane (ilm) vitreo retinal surgery vitrectomy
a systematic echography during intubation procedure to predict cardiovascular collapse

Conditions: Intubation

Summary: in the operating room, most intubation procedures (ip) are scheduled and performed on hemodynamically stable patients. in the icu, ip is frequently performed in emergent patients, because of unstable hemodynamics and/or acute respiratory failure, and complicated by a subsequent cardiovascular collapse. transthoracic echocardiography (tte) has become readily available in most icus for several years. echocardiography enables to perform a noninvasive hemodynamic evaluation (cardiac function and volemia status). we hypothesized that performing a tte prior to ip may help to predict cardiovascular collapse and its components.


Eligibility criteria:
inclusion criteria: patient requiring endotracheal intubation exclusion criteria: * age \< 18 yrs * pregnancy * amputation of a lower limb * passing leg raising contraindication: intracranial hypertension with invasive monitoring, fracture of the pelvis or limbs * patients under administrative protective measures * severe cardiovascular collapse before intubation * severe cardiogenic pulmonary oedema
effects of fascial distortion model with and without neuromuscular inhibition in patients with piriformis syndrome

Conditions: Piriformis Syndrome

Summary: the aim of study will be to find the effects of fascial distortion model (fdm) with and without the integrated neuromuscular inhibition technique (init) in piriformis syndrome.

piriformis syndrome is a misdiagnosed cause of sciatica leg or buttock pain and disability. the male and female incidence ratio of ps is 6.1. the fascial distortion model is a targeted manual technique and decodes categorized manual gestures (pain-related body language) to 6 pathophysiological mechanisms involved in the etiology of pain. integrated neuromuscular inhibition technique(init) is a combination of muscle energy technique(met) and positional release technique(prt). all previous studies in which integrated neuromuscular inhibition technique(init) and fascial distortion model(fdm) has been performed on different muscles of the body has shown greater improvement as compared to other techniques. comparative effects of fascial distortion model with integrated neuromuscular inhibition technique and fascial distortion model on piriformis syndrome has not been addressed yet. there is very limited data available on this protocol. therefore, this study aims to compare the effects of facial distortion model with and without integrated neuromuscular inhibition technique.

Eligibility criteria:
inclusion criteria: * unilateral buttock pain and radiculopathy due to spasms of the piriformis muscle or sciatic nerve compression. * aggravate buttock pain in sitting and limited slr. * patient with freiberg test positive. * patient with fair test positive. * patient with positive pace test. * patient with positive beatty's maneuver. exclusion criteria: * lumbar spinal pathology and recent injury around the hip, sacroiliac joint, or lumbar spine. * patient with a positive faber test * sij pathology like sij dysfunction, innominate anterior or posterior rotation dysfunction, etc. * deep gluteal syndrome. * recent surgery like hip arthroplasty, surgical emplacement of a gluteal implant (buttock prosthesis); lip sculpture (fat transfer and liposuction); and body contouring (surgery and lip sculpture).

Keywords: integrated neuromuscular inhibition technique muscle energy technique piriformis syndrome positional release technique fascial distortion model